By Chad Savage, M.D.
I love the COVID-19 vaccines.
I am truly blown away by the new mRNA vaccines and how amazingly effective they are. I love it so much that I eagerly lined up for my own vaccination when it became available. As a middle-aged man, I recognize that my risk of serious complications or death is increasing as I age, so I am happy to be protected by this incredible new technology.
However, that does not mean I am ready to give the COVID-19 vaccine to my kids. Children are at a vanishingly low risk of dying from COVID, and any vaccine to mitigate such a low risk should be safer than the minimal risk it is attempting to mitigate. Basically, the cure cannot be worse than the disease.
Thus far, the COVID-19 vaccines being distributed in the United States are approved by the U.S. Food and Drug Administration (FDA) for adults under the Emergency Use Authorization (EUA). Pfizer and Moderna are now seeking an EUA for COVID vaccine use in children. Preliminary study results are highly encouraging.
But is an EUA the correct mechanism needed for approval of childhood COVID vaccines? The expedited EUA process was appropriate when trying to rapidly make available a vaccine for high-risk adults, for whom time was of the essence. For children, the hurried pace may not be needed.
Children – 7,900 Times Safer
Children are not dying in large numbers from this pandemic. Rather, COVID-19 drastically disproportionately affects the elderly, who are up to 7,900 times more likely to die from COVID than are children. Eighty-one percent of COVID deaths occur in those age 65 and older, many of whom with dementia or other advanced diseases. Any COVID vaccine for children must be fully scrutinized and incredibly safe. The purpose of the EUA is to mitigate an urgent risk, and that risk does not exist with children.
Under the EUA, vaccines must be shown to be safe two months after administration. Though unlikely, it is conceivable that delayed negative side-effects could occur which could go undetected by this approach and only show up in post-marketing data after millions of doses have been given. This small risk may be acceptable in high-risk elderly, but if they were to occur in children with their longer life expectancy, they would have many more years to potentially suffer these theoretical harms. The more rigorous standard FDA approval process would better weed out these delayed effects and provide more confidence to parents considering giving them to their children.
The standard authorization approach also assesses the manufacturing process more thoroughly. It is possible that such an assessment would have headed off the recent loss of 15 million Johnson and Johnson vaccines from an ingredient mix-up.
Though there are attempts to be as thorough as possible with an EUA, we simply do not know as much about a vaccine authorized under an EUA compared to the traditional approach. An example of this is that Pfizer recently changed the storage requirement for their mRNA vaccine. Though it may seem like a small point, what this demonstrates is that we are still learning about these vaccines.
It is already presumed that COVID may be with us for the long haul. As it is currently unknown how long COVID vaccine immunity will last, children are likely to require repeated doses of the vaccine. This is meaningful, as flu-like side effects are more common in young people and could be more severe than the symptoms experienced by the infection itself. This manifested in my own family as my son, who contracted COVID, experienced fewer symptoms from the infection than I did from the vaccine.
As their risk is low, causing our children to experience repeated side effects while deriving minimal absolute risk reduction from the vaccine could unnecessarily create a generation opposed to vaccinations.
The Better Approach
A better approach may be to skip the COVID vaccination of children altogether. Instead, consider making the COVID vaccines age- and risk-dependent, as is already done for vaccines such as Shingrix (shingles) and the Pneumococcal(pneumonia) vaccine. These vaccines are not given to healthy adolescents, but instead to high-risk groups for whom the benefit may justify the side effects.
I am a big fan of the vaccines, for the correct people. It may prove later on that children are in this group. However, we should not rush vaccine approval if the urgency does not exist. We should take a cautious, reasoned approach regarding vaccinating our children for COVID-19. It reminds me of the advice I received when I was on the hospital code team: “when responding to a code, the first pulse you should check is your own.”
Chad Savage, M.D. is an internist, father, founder of YourChoice Direct Care and policy advisor to The Heartland Institute, which co-publishes Health Care News. This article appeared in Townhall on April 3, 2021. . Reprinted with permission.
This commentary is from a doctor??? “Amazingly effective”???
We have no idea what the long-term safety and efficacy of these vaccines. Since when do we believe and trust a company’s assessment of their own product? Particularly a company that has been excluded from liability for defective products!
Vaccines go through YEARS of trials and surveillance before they are authorized, and those are traditional vaccines. The Pfizer and Moderna vaccines are using an entirely new technology that has failed in its original purpose of cancer treatment/mitigation.
I would SERIOUSLY consider retracting this from your website. It is misleading and there is no disclosure of any conflicts of interest, as is required by ethical medical practice.
Dr. Savage wanted to establish the fact that he is not against vaccines. His comment was based on the efficacy/safety trials that the companies conducted to win emergency use authorization for adults. This article was commentary and he is expressing an opinion. The point of his article is that the COVID-19 vaccines are not appropriate for individuals under the age of 18.
HCN has written a number of news articles on questions concerning vaccine safety and efficacy and we will continue to do so as more information develops. Thanks for your feedback.